Entropy Technologies LP Increases Stake in Boston Scientific Corporation $BSX

Entropy Technologies LP increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 137.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 155,026 shares of the medical equipment provider’s stock after purchasing an additional 89,743 shares during the quarter. Boston Scientific accounts for about 0.8% of Entropy Technologies LP’s investment portfolio, making the stock its 10th largest holding. Entropy Technologies LP’s holdings in Boston Scientific were worth $14,782,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in BSX. Norges Bank bought a new position in Boston Scientific during the fourth quarter worth $2,199,395,000. Egerton Capital UK LLP lifted its stake in Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares during the last quarter. Maverick Capital Ltd. bought a new position in Boston Scientific during the fourth quarter worth $280,735,000. Arrowstreet Capital Limited Partnership lifted its stake in Boston Scientific by 31.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 11,035,628 shares of the medical equipment provider’s stock valued at $1,052,247,000 after buying an additional 2,668,230 shares during the last quarter. Finally, Alphinity Investment Management Pty Ltd bought a new stake in Boston Scientific in the fourth quarter valued at $252,918,000. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 9,800 shares of company stock worth $554,012 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
• Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
• Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation (NYSE:BSX) – Free Report
• Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Boston Scientific Price Performance

Shares of NYSE BSX opened at $46.83 on Friday. Boston Scientific Corporation has a fifty-two week low of $45.99 and a fifty-two week high of $109.50. The firm’s 50-day simple moving average is $56.37 and its 200 day simple moving average is $74.95. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The stock has a market cap of $69.60 billion, a P/E ratio of 19.59, a P/E/G ratio of 0.88 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the previous year, the business earned $0.75 earnings per share. The company’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

A number of equities research analysts have issued reports on BSX shares. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Truist Financial cut their target price on Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a research note on Thursday, June 4th. Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Mizuho cut their target price on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Finally, UBS Group cut their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $85.08.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.